MTR: Key Enzyme in Methionine Synthesis (G4548)

Target Name: MTR

NCBI ID: G4548

Content of Review Report on MTR Target / Biomarker

MTR

MTR: Key Enzyme in Methionine Synthesis

MTR (Cobalamin-dependent methionine synthase) is a protein that plays a crucial role in the synthesis of methionine, a crucial amino acid that is involved in the structure and function of many proteins in the body. Methionine is also a precursor to many other molecules , including proteins, nucleic acids, and neurotransmitters.

MTR is a key enzyme in the pathway of methionine synthesis, and it is dependent on the availability of cobalamin, a vitamin B9 that is involved in the synthesis of methionine. Methionine synthase is a complex protein that consists of four subunits, and it is expressed in a variety of tissues and cells in the body.

MTR is involved in the synthesis of methionine from its precursor, L-methionine, which is obtained from the diet or from supplemental sources. The first step in the synthesis of L-methionine is the conversion of tryptophan, an amino acid found in many proteins , to L-tryptophan by the enzyme tryptophan aminotransferase (TAT).

Once L-tryptophan is converted to L-methionine, MTR is involved in the second step of its synthesis, the conversion of L-methionine to S-adenosylmethionine (S-AdoMeth) by the enzyme S-adenosylmethionine synthase (SAM ). In this step, MTR uses its prosthetic group Co-A to convert L-methionine to S-AdoMeth, which is then further converted to S-adenosylL-methionine (S-AdoLMeth) by the enzyme A-adenosine Base L-methionine synthase (ALMS).

S-AdoLMeth is the final step in the synthesis of methionine, and it is converting L-AdoLMeth to L-methionine, which is then transported to the cytoplasm and used by the enzyme tryptophan hydroxylase (THH) to form L-tryptophan, the first step in the synthesis of methionine.

MTR is a protein that is expressed in many tissues and cells in the body, including the brain, heart, liver, and kidneys. It is involved in the synthesis of methionine from its precursor, L-methionine, and it is a key enzyme in the pathway of methionine synthesis. MTR is a potential drug target or biomarker for a variety of diseases, including Alzheimer's disease, Parkinson's disease, and several others.

In conclusion, MTR (Cobalamin-dependent methionine synthase) is a protein that plays a crucial role in the synthesis of methionine, a crucial amino acid that is involved in the structure and function of many proteins in the body. Methionine is also a precursor to many other molecules, including proteins, nucleic acids, and neurotransmitters. MTR is a key enzyme in the pathway of methionine synthesis, and it is dependent on the availability of cobalamin, a vitamin B9 that is involved in the synthesis of methionine. MTR is expressed in many and tissues cells in the body, including the brain, heart, liver, and kidneys, and it is a potential drug target or biomarker for a variety of diseases.

Protein Name: 5-methyltetrahydrofolate-homocysteine Methyltransferase

Functions: Catalyzes the transfer of a methyl group from methylcob(III)alamin (MeCbl) to homocysteine, yielding enzyme-bound cob(I)alamin and methionine in the cytosol (PubMed:16769880, PubMed:27771510, PubMed:17288554). MeCbl is an active form of cobalamin (vitamin B12) used as a cofactor for methionine biosynthesis. Cob(I)alamin form is regenerated to MeCbl by a transfer of a methyl group from 5-methyltetrahydrofolate (PubMed:16769880, PubMed:27771510, PubMed:17288554). The processing of cobalamin in the cytosol occurs in a multiprotein complex composed of at least MMACHC, MMADHC, MTRR (methionine synthase reductase) and MTR which may contribute to shuttle safely and efficiently cobalamin towards MTR in order to produce methionine (PubMed:16769880, PubMed:27771510)

The "MTR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets